Aptorum [APM_US]: Commencement of Sale of NativusWellR in Hong Kong, Updates on RPIDD
Aptorum [APM_US; US$39 million market cap] reported revenue of $527,462 for the 1H2022 and had US$7.2 million of cash and restricted cash as...
726 Views
Aptorum [APM_US]: First Patent Granted for RPIDD, ALS-4 and SACT-1 Phase 1 Clinical Trial Completed
Aptorum [APM_US; US$37 million market cap] has announced that the US Patent and Trademark Office (US PTO) has granted the first patent on their...
68 Views
Aptorum_US: FDA Grants Orphan Drug Designation - SACT-1, First Patent for SACT-1-Cancer Treatment
Aptorum Group Ltd. [APM_US; US$60 million market cap] announced that the United States Food and Drug Administration (FDA) Office has granted Orphan...
1.4k Views
Aptorum: Completion-Phase I Clinical Trial: ALS-4 & SACT-1, Commencement-Clinical Validation: RPIDD
Aptorum Group Limited [APM_US; US$53 million market cap] announced that its subsidiary company, Aptorum Innovations Holding Limited (Aptorum...
1.4k Views
Aptorum [APM_US]: USFDA Clearance to Open IND Clinical Trials on SACT-1; Further Progress....
In September 2021, Aptorum Group [APM_US; US$95 million market cap] received clearance from the US FDA to open an IND to conduct clinical trials on...
1.4k Views